Showing 1 - 20 results of 30,726 for search '(( care test decrease ) OR ((( _ larger decrease ) OR ( _ ((a decrease) OR (small decrease)) ))))', query time: 0.57s Refine Results
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6

    Why does task performance decrease with burst length? by Swathi Anil (17382903)

    Published 2025
    “…See <a href="http://www.ploscompbiol.org/article/info:doi/10.1371/journal.pcbi.1013125#pcbi.1013125.s001" target="_blank">S1 Appendix</a>.…”
  7. 7
  8. 8
  9. 9

    The introduction of mutualisms into assembled communities increases their connectance and complexity while decreasing their richness. by Gui Araujo (22170819)

    Published 2025
    “…(C) Mutualism also promotes an increase in network connectance when introduced into assembled communities, while stopping mutualistic interactions from entering an assembled system slowly decreases it. (D) As a result, the introduction of mutualistic interactions promotes a growth in complexity in communities where it was once established as low, while stopping the introduction of further mutualistic interactions causes a slight decrease in complexity. …”
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14

    DataSheet1_Decreasing viscosity and increasing accessible load by replacing classical diluents with a hydrotrope in liquid–liquid extraction.docx by Asmae El Maangar (19690522)

    Published 2025
    “…We show that using hydrotropes as a diluent decreases the viscosity of solutions by more than a factor of ten, even under high load by extracted cations. …”
  15. 15

    Cascade of care by HCV testing model. by Bao Vu Ngoc (14551955)

    Published 2025
    “…HCVST at CBOs and clinics was more costly than standard testing ($636 vs. $408 and $605 vs. $218). HCVST was still costlier at CBOs but cheaper at clinics compared to standard testing when kit costs decreased to $2 ($417 vs. $218 and $357 vs. $408). …”
  16. 16

    Table 1_Previous treatment decreases efficacy of pralsetinib in RET fusion-positive non-small-cell lung cancer.doc by Lei Wang (6656)

    Published 2025
    “…Background<p>Pralsetinib is a selective RET inhibitor. The ARROW trial revealed that RET fusion-positive non-small-cell lung cancer (NSCLC) can benefit from pralsetinib with tolerable adverse events (AEs). …”
  17. 17
  18. 18
  19. 19
  20. 20